CTA-PB

E. I. du Pont de Nemours and Company - Q1 2000 10-Q Summary

Business Context and Reporting Period

This Form 10-Q covers the quarterly period ended March 31, 2000, for E. I. du Pont de Nemours and Company (DuPont). The filing was submitted on May 5, 2000. DuPont operates globally in approximately 70 countries, deriving roughly half of its revenues from outside the United States. The company is a diversified science and technology enterprise with segments including Agriculture & Nutrition, Nylon, Performance Coatings, Pharmaceuticals, and Specialty Fibers.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Sales increased 21% to a record $7.6 billion. This was driven by 18% growth from the Herberts and Pioneer acquisitions and 6% volume growth from comparable businesses. Currency effects reduced sales by 3% due to a stronger U.S. dollar.
• Profitability: Income from continuing operations rose to $803 million from $628 million. Excluding one-time items, income increased 20% to $898 million. Acquisitions and lower pension costs added approximately $200 million to net income, partially offset by higher raw material costs and currency headwinds totaling $110 million.
• Segment Performance:
  • Performance Coatings & Polymers: Sales up 44% and earnings up 28%, largely due to the Herberts acquisition.
  • Pioneer: Sales of $921 million with underlying after-tax operating income of $172 million, compared to a $7 million loss in Q1 1999, reflecting full ownership consolidation.
  • Agriculture & Nutrition: Earnings declined 36% due to weakness in U.S. crop protection products.
  • Pharmaceuticals: Earnings down 28% due to higher R&D expenses and lower sales of "Coumadin," despite growth from "Sustiva."
• Cash Flow: Cash provided by continuing operations improved significantly to $335 million from $147 million, though working capital requirements increased seasonally.

Guidance, Outlook, and Risks

• Restructuring: DuPont announced an expanded restructuring for its Performance Coatings business to consolidate assets following the Herberts acquisition. This involves eliminating approximately 900 positions and is expected to yield $80 million in annual pretax savings, with a one-time charge anticipated in Q2 2000.
• Joint Ventures: Talks on a polyester filament yarn joint venture with Akra-Teijin were discontinued. A new manufacturing alliance with Unifi, Inc. was signed to optimize polyester filament production, effective June 1, 2000.
• Legal Contingencies:
  • "Benlate" Litigation: Approximately 150 cases remain pending regarding alleged crop damage. A recent Texas jury award of ~$69 million is expected to be reduced to ~$23 million due to state law caps on punitive damages; DuPont plans to appeal.
  • Environmental: Ongoing proceedings with the EPA regarding triazine herbicide labels and a DOJ settlement in principle regarding a 1995 oleum release in Kentucky.
• Outlook: Management intends to limit capital spending to approximately $2 billion for the year and aims to reduce net debt to increase financial flexibility. "Cozaar" equalization earnings are not expected to materialize until 2001.

Investor Verification Checklist

• Verify the impact of the $347 million noncash charge related to the Pioneer inventory step-up on future cost of goods sold.
• Monitor the execution of the Performance Coatings restructuring and the timing of the associated one-time charges in Q2 2000.
• Assess the resolution of the "Benlate" litigation, specifically the appeal of the Texas jury award and the status of the remaining 150 pending cases.
• Track the integration of the Herberts acquisition and the realization of the projected $80 million in annual savings.
• Review the performance of the Pharmaceuticals segment, specifically the sales trajectory of "Sustiva" versus the decline in "Coumadin."